Gilead Sciences, Inc. GILD
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About GILD
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Gilead Sciences, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines for life-threatening diseases. The company primarily operates in the biotechnology and pharmaceutical industries, with major therapeutic areas including HIV/AIDS, viral hepatitis, oncology, and inflammatory diseases. Gilead generates most of its revenue from antiviral therapies, particularly HIV treatments, while oncology has become an increasingly important growth area following recent acquisitions and product launches. Its portfolio includes therapies marketed under brands such as Biktarvy, Descovy, Genvoya, Trodelvy, Yescarta, and Veklury.
Gilead was founded in 1987 by Michael L. Riordan and evolved from a small biotechnology research company into one of the largest global antiviral drug developers. The company expanded significantly through internal drug development and acquisitions, including the purchases of Pharmasset in 2011, which strengthened its hepatitis C franchise, and Immunomedics in 2020, which expanded its oncology portfolio. Gilead is widely recognized for its leadership in HIV therapeutics, supported by extensive clinical research capabilities, long-term physician relationships, and a large global commercial infrastructure.
Business Operations
Gilead organizes its business primarily around therapeutic and commercial product categories, with major operations spanning HIV, oncology, liver disease, and cell therapy. The company reports product sales across key areas including HIV, oncology, liver disease, and other antiviral products in filings such as its Form 10-K submitted to the U.S. Securities and Exchange Commission. HIV medicines represent the company’s largest revenue driver, with products such as Biktarvy maintaining leading market positions in multiple countries. Oncology operations include antibody-drug conjugates and CAR-T cell therapies through products associated with Kite Pharma and Immunomedics. The company also markets antiviral treatments including Veklury (remdesivir), which saw elevated demand during the COVID-19 pandemic.
Gilead operates globally through research facilities, manufacturing partnerships, and commercial organizations across North America, Europe, and Asia-Pacific. The company controls a broad intellectual property portfolio related to antivirals, cell therapy technologies, and oncology platforms. Key subsidiaries include Kite Pharma, focused on cell therapy treatments, and partnerships with firms such as Galapagos NV for inflammatory disease research. Gilead also collaborates with academic institutions, biotechnology firms, and public health organizations to expand treatment access and accelerate drug development.
Strategic Position & Investments
Gilead’s strategic direction centers on sustaining leadership in HIV while expanding oncology and inflammatory disease capabilities. The company has invested heavily in next-generation HIV therapies, long-acting treatment approaches, and oncology platforms. Major acquisitions have included Pharmasset, which enabled blockbuster hepatitis C treatments, and Immunomedics, which added the Trodelvy oncology franchise. Gilead has also invested in cell therapy through Kite Pharma, positioning itself in personalized cancer treatment markets.
The company continues to allocate capital toward research and development, strategic licensing agreements, and targeted acquisitions. Emerging focus areas include immunology, oncology biologics, and advanced therapies involving engineered immune cells. Gilead has also pursued partnerships in artificial intelligence-driven drug discovery and clinical research optimization, although these initiatives remain smaller relative to its core pharmaceutical operations. Its strategy emphasizes diversification beyond antivirals while leveraging established expertise in infectious diseases and global commercialization.
Geographic Footprint
Gilead Sciences is headquartered in Foster City, California, and maintains operations across major global pharmaceutical markets. The company has a substantial commercial presence in North America, Europe, and Asia-Pacific, with products distributed in more than 35 countries and access programs extending into developing regions. The United States remains its largest market by revenue, though international sales contribute a significant portion of overall product revenue.
The company supports international operations through regional offices, manufacturing relationships, and research collaborations. Gilead has invested in expanding treatment access in Africa, Latin America, and parts of Asia through licensing agreements and partnerships aimed at increasing availability of HIV and antiviral medicines. Its global reach is reinforced by long-standing relationships with healthcare providers, governments, and multilateral public health organizations.
Leadership & Governance
Gilead’s leadership structure combines pharmaceutical commercialization expertise with biotechnology research and development capabilities. The company’s governance framework is overseen by a board of directors and executive leadership team responsible for strategic execution, capital allocation, and regulatory compliance. Current leadership has emphasized long-term innovation in virology and oncology while balancing shareholder returns with sustained research investment.
Key executives include:
- Daniel O’Day – Chairman and Chief Executive Officer
- Andrew Dickinson – Chief Financial Officer
- Merdad Parsey – Chief Medical Officer
- Dietmar Berger – Chief Medical Officer, Oncology
- Johanna Mercier – Chief Commercial Officer
- Flavius Martin – Executive Vice President, Research
- Roberto Izzo – Executive Vice President, Pharmaceutical Development and Manufacturing
The company’s leadership philosophy has focused on scientific innovation, expansion into high-growth therapeutic areas, and strengthening Gilead’s position as a diversified biopharmaceutical company. Public statements in earnings materials and SEC filings indicate a continued emphasis on oncology expansion, lifecycle management of HIV products, and disciplined business development activity.